Ren Shuying
Deng Fangming
Du Zhongdong
Yang Xiaodong
 Email src
Xie Lijian
Wang Hong
Jiao Fuyong
 Email src
Pediatrics, Xi’an Medical University, Xi’an, Shaanxi, China
Chinese Journal of Contemporary Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China
Department of Pediatrics, Beijing Children’s Hospital of Capital University of Medical, Beijing, China
Department of Pediatrics, Children’s Hospital of Medical School of Shanghai Jiaotong University, Shanghai, China
Department of Pediatrics, Shengjing Hospital affiliated with China Medical University, China
Department of Pediatrics of Children’s Hospital, Shaanxi Provincial People’s Hospital, Xi’an, Shaanxi, China
Received: 7 September 2023 / Revised: 29 October 2023 / Accepted: 2 November 2023 / Published: 30 March 2024


Introduction and aim. Kawasaki disease (KD) is an acute vasculitis with unknown etiology, usually occurring in chil dren under 5 years old. This article will summarize the three consensuses formulated in China about KD.

Material and methods. English databases for consensus search include UpToDate, BMJ Clinical Evidence, National Guideline Clearinghouse, Joanna Briggs Institute Library, Cochrane Library, and PubMed, etc.; Chinese databases in clude China Biomedical Literature Service, China Knowledge Network, Wanfang database, etc. All literature searches ended on February 28, 2022.

Analysis of the literature. KD is a common acquired heart disease in children and can lead to severe complications such as coronary injury. However, intravenous immunoglobulin (IVIG) combined with oral aspirin (Asp) is currently recognized as the most effective treatment in KD acute stage and the first-line treatment to prevent cardiovascular complications. Glucocorticoid (GC) is mainly used for KD patients with a high risk of coronary artery aneurysm (CAA), no immunoglobulin response, and confirmed CAA. There are already consensus guidelines on diagnosing and treat ing KD in different countries. This article summarizes the relevant expert consensus on aspirin, glucocorticoids and IVIG for the treatment of Kawasaki disease in China.

Conclusion. Still, there are inconsistent opinions in the literature on the mechanism, optimal timing, and dosage of medication for KD.



Shuying R, Fangming D, Zhongdong D, Xiaodong Y, Lijian X, Hong W, Fuyong J. Consensus Committee of experts on Kawasaki Disease and Chinese Journal of Contemporary Pediatrics – the expert consensuses on intravenous immunoglobulin, aspirin, and glucocorticoid. Eur J Clin Exp Med. 2024;22(1):179–187. doi: 10.15584/ejcem.2024.1.8.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited